Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 384,100 shares, a growth of 221.7% from the December 31st total of 119,400 shares. Based on an average trading volume of 493,500 shares, the short-interest ratio is presently 0.8 days. Currently, 2.1% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Raymond James decreased their price target on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.

Institutional Investors Weigh In On Xilio Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of Xilio Therapeutics in the second quarter valued at $32,000. Geode Capital Management LLC lifted its stake in Xilio Therapeutics by 85.0% in the third quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after acquiring an additional 155,337 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Xilio Therapeutics by 18.3% in the second quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after acquiring an additional 45,554 shares during the last quarter. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Trading Up 2.5 %

Shares of XLO stock opened at $0.74 on Wednesday. The firm’s fifty day moving average price is $1.02 and its two-hundred day moving average price is $0.94. Xilio Therapeutics has a 1 year low of $0.50 and a 1 year high of $1.93. The firm has a market capitalization of $32.52 million, a P/E ratio of -0.43 and a beta of -0.25.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. As a group, equities research analysts forecast that Xilio Therapeutics will post -1.14 EPS for the current fiscal year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.